Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-13027 and/or HY-0102 plus AG chemotherapy for metastatic pancreatic ductal adenocarcinoma
CTR20250906Phase 2Active
- Sponsor
- Shanghai HyaMab Biotechnology
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YL-13027, HY-0102, gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Shanghai HyaMab Biotechnology. Started Mar 2025; status: active.
02
Drugs
YL-13027HY-0102gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20250906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250906.